Co-Authors
This is a "connection" page, showing publications co-authored by ISSAM I RAAD and SAMUEL SHELBURNE.
Connection Strength
1.499
-
Identification and characterization of catheter-related bloodstream infections due to viridans group streptococci in patients with cancer. Am J Infect Control. 2014 Oct; 42(10):1127-9.
Score: 0.491
-
In vitro activity of cefepime/taniborbactam and comparator agents against Gram-negative bacterial bloodstream pathogens recovered from patients with cancer. JAC Antimicrob Resist. 2024 Apr; 6(2):dlae060.
Score: 0.238
-
The in vitro activity of delafloxacin and comparator agents against bacterial pathogens isolated from patients with cancer. JAC Antimicrob Resist. 2023 Apr; 5(2):dlad034.
Score: 0.221
-
In vitro activity of eravacycline and comparator agents against bacterial pathogens isolated from patients with cancer. JAC Antimicrob Resist. 2023 Apr; 5(2):dlad020.
Score: 0.220
-
Central line-associated bloodstream infections caused by Staphylococcus aureus in cancer patients: Clinical outcome and management. Ann Med. 2014 May; 46(3):163-8.
Score: 0.117
-
In vitro activity of imipenem/releactam and comparator agents against clinical bacterial isolates from patients with cancer. J Glob Antimicrob Resist. 2022 06; 29:1-6.
Score: 0.051
-
Activity of Cefiderocol and Comparators against Isolates from Cancer Patients. Antimicrob Agents Chemother. 2020 04 21; 64(5).
Score: 0.045
-
Clinical Outcomes Associated With Linezolid Resistance in Leukemia Patients With Linezolid-Resistant Staphylococcus epidermidis Bacteremia. Open Forum Infect Dis. 2018 Jul; 5(7):ofy167.
Score: 0.040
-
In vitro activity of tedizolid and comparator agents against clinical Gram-positive isolates recovered from patients with cancer. Diagn Microbiol Infect Dis. 2018 Aug; 91(4):351-353.
Score: 0.039
-
In vitro activity of ceftaroline and comparator agents against Gram-positive and Gram-negative clinical isolates from cancer patients. Int J Antimicrob Agents. 2017 Apr; 49(4):416-421.
Score: 0.036